The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | VIBER-M: venetoclax, iberdomide, & dexamethasone for multiple myeloma with t(11;14) in early relapse
Hang Quach, MBBS(Hons), SpecCertOC, FRACP, FRCPA, MD, The University of Melbourne, Melbourne, Australia, discusses the interim analysis of the VIBER-M trial (ALLG MM25; ACTRN12624000320626), a Phase Ib/II study investigating the efficacy and safety of venetoclax, iberdomide, and dexamethasone in patients with multiple myeloma and the t(11;14) translocation in first or second relapse. Prof. Quach highlights that, although follow-up is still short, early data are encouraging. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
